| Press Releases |
|
January 31, 2012 |
MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE RESULTS FROM THE PHASE 3 AFFIRM TRIAL OF MDV3100 IN PROSTATE CANCER PATIENTS WHO RECEIVED PRIOR CHEMOTHERAPY |
January 06, 2012 |
ASTELLAS AND THERAVANCE ANNOUNCE TERMINATION OF LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT FOR VIBATIV® (TELAVANCIN) FOR INJECTION |
January 03, 2012 |
AVEO AND ASTELLAS ANNOUNCE TIVOZANIB SUCCESSFULLY DEMONSTRATED PROGRESSION-FREE
SURVIVAL SUPERIORITY OVER SORAFENIB IN PATIENTS WITH ADVANCED RENAL CELL CANCER IN PHASE
3 TIVO-1 TRIAL |
December 21, 2011 |
ZOGENIX AND ASTELLAS AGREE TO END CO-PROMOTION FOR
SUMAVEL DOSEPRO EFFECTIVE MARCH 31, 2012 |
December 01, 2011 |
ASTELLAS ADDS TWO KEY SENIOR EXECUTIVES AT AGENSYS, INC. |
November 11, 2011 |
ASTELLAS SIGNS UNITED NATIONS GLOBAL COMPACT |
November 03, 2011 |
MEDIVATION AND ASTELLAS ANNOUNCE POSITIVE SURVIVAL DATA FROM INTERIM ANALYSIS OF PHASE 3 AFFIRM TRIAL OF MDV3100 IN MEN WITH ADVANCED PROSTATE CANCER |
September 28, 2011 |
SEVEN CHICAGO AREA SERVICE PROJECTS TOP OFF CHANGING TOMORROW DAY AT ASTELLAS |
August 28, 2011 |
ASTELLAS PHARMA INC.: ANNOUNCEMENT OF REGULATORY SUBMISSION FOR MIRABEGRON (YM178), A TREATMENT FOR OVERACTIVE BLADDER, IN U.S. AND EUROPE |
August 15, 2011 |
ASTELLAS EXPANDS LEADERSHIP TEAM WITH SENIOR VICE PRESIDENT OF CORPORATE STRATEGY AND GOVERNMENT AFFAIRS |
July 26, 2011 |
MERCK TO ACQUIRE RIGHTS TO VERNAKALANT I.V. IN CANADA, MEXICO AND THE UNITED STATES FROM ASTELLAS |
June 06, 2011 |
ASTELLAS ANNOUNCES NEW STUDY RESULTS SHOWING INCREASED SURVIVAL RATE FOR METASTATIC PANCREATIC CANCER |
June 03, 2011 |
TARCEVA NEARLY DOUBLED THE TIME PEOPLE WITH A GENETICALLY DISTINCT TYPE OF LUNG CANCER LIVED WITHOUT THEIR DISEASE GETTING WORSE |
May 19, 2011 |
ASTELLAS ANNOUNCES VICE PRESIDENT OF SALES AND MARKETING FOR U.S. ONCOLOGY FRANCHISE |
May 17, 2011 |
ASTELLAS ANNOUNCES POSITIVE PHASE III RESULTS SHOWING MIRABEGRON IMPROVES KEY OAB SYMPTOMS |
May 03, 2011 |
ASTELLAS STRENGTHENS GLOBAL DEVELOPMENT TEAM |
January 28, 2011 |
EARLY SUCCESSFUL READOUT OF TARCEVA STUDY IN A DISTINCT FORM OF LUNG CANCER |
January 10, 2011 |
ASTELLAS TO REVIEW STRATEGIC BUSINESS ALTERNATIVES FOR PROSIDION SUBSIDIARY |
November 16, 2010 |
2010 NSTA NEW SCIENCE TEACHER ACADEMY FELLOWS ANNOUNCED
|
November 02, 2010 |
ASTELLAS DONATES 150 LAPTOP COMPUTERS TO HELP INNER-CITY CHICAGO STUDENTS
ASTELLAS ANNOUNCES RETIREMENT OF DONALD RICE AND APPOINTMENT OF SEF KURSTJENS AS CEO AND PRESIDENT OF AGENSYS, INC.
|
October 28, 2010 |
NEW SURVEY SHOWS REAL-WORLD ACTIVITIES CAN HELP REINVIGORATE STUDENT INTEREST IN SCIENCE EDUCATION
|
September 27, 2010 |
LEXISCAN® (REGADENOSON) INJECTION STUDY IN SUBJECTS WITH ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) PRESENTED AS LATE-BREAKER AT AMERICAN SOCIETY OF NUCLEAR CARDIOLOGY 2010
NEW SMARTPHONE APP LAUNCHES FOR CARDIAC IMAGING TEST
|
September 17, 2010 |
ASTELLAS MOBILIZES 1,300+ EMPLOYEES IN THE AMERICAS TO PARTICIPATE IN FIRST ANNUAL 'CHANGING TOMORROW DAY'
|
September 15, 2010 |
ASTELLAS AWARDS SCHOLARSHIPS TO 12 TRANSPLANT RECIPIENTS AND DONORS WHO EMBODY HOPE, COURAGE AND ACHIEVEMENT
|
September 15, 2010 |
ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2011 ROSE PARADE®
|
September 1, 2010 |
AGENSYS, AN AFFILIATE OF ASTELLAS, ANNOUNCES INITIATION OF PHASE I CLINICAL TRIAL OF AGS-16M8F FOR RENAL CANCER
|
June 28, 2010 |
ASTELLAS ANNOUNCES ORAL PRESENTATION OF SGLT2 INHIBITOR DETAILING
SAFETY AND EFFICACY IN PATIENTS WITH TYPE 2 DIABETES AT THE
AMERICAN DIABETES ASSOCIATION MEETING
|
June 9, 2010 |
ASTELLAS COMPLETES ACQUISITION OF OSI PHARMACEUTICALS
|
June 8, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF TENDER OFFER FOR SHARES OF OSI
|
June 3, 2010 |
ASTELLAS ANNOUNCES SUCCESSFUL COMPLETION OF INITIAL TENDER OFFER FOR SHARES OF OSI AND ANNOUNCES SUBSEQUENT OFFER PERIOD
|
May 17, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO JUNE 2, 2010
|
May 16, 2010 |
ASTELLAS PHARMA INC. TO ACQUIRE OSI PHARMACEUTICALS, INC.
|
May 03, 2010 |
NEW SCIENCE EDUCATION PROGRAM RESPONDS TO PRESIDENT'S
CALL TO HELP YOUNG PEOPLE EXCEL IN SCIENCE
|
April 29, 2010 |
GOVERNOR QUINN ANNOUNCES ASTELLAS PHARMA U.S.
CHOOSES ILLINOIS FOR NEW HEADQUARTERS
|
April 29, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED APPROVAL IN THE EUROPEAN UNION
FOR MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
April 26, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT "RADIANT", AN INTERNATIONAL PHASE III TARCEVA
ADJUVANT TRIAL IN NON-SMALL CELL LUNG CANCER, COMPLETES ENROLLMENT
|
April 23, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO MAY 17, 2010
|
April 16, 2010 |
FDA APPROVES TARCEVA AS A MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER
|
April 05, 2010 |
NUMBER OF AMERICANS WILLING TO DONATE ORGANS RISES,
BUT STILL NOT KEEPING PACE WITH NEED
|
March 31, 2010 |
EXPIRATION DATE OF OSI OFFER EXTENDED TO APRIL 23, 2010
|
March 29, 2010 |
ASTELLAS SIGNS CONFIDENTIALITY AGREEMENT WITH OSI
|
March 19, 2010 |
ASTELLAS ANNOUNCES CHANGES TO DIRECTOR NOMINEES FOR ELECTION TO OSI
PHARMACEUTICALS' BOARD OF DIRECTORS
|
March 19, 2010 |
ASTELLAS ANNOUNCES EXPIRATION OF HSR WAITING PERIOD FOR OSI TENDER OFFER
|
March 19, 2010 |
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA® RECEIVED A POSITIVE OPINION FROM HEALTH AUTHORITIES IN THE EUROPEAN UNION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
March 16, 2010 |
ASTELLAS ANNOUNCES FULL SLATE OF INDEPENDENT DIRECTOR NOMINEES FOR ELECTION AT OSI
PHARMACEUTICALS' 2010 ANNUAL STOCKHOLDERS MEETING
|
March 15, 2010 |
ASTELLAS RESPONDS TO OSI PHARMACEUTICALS' REJECTION
|
March 02, 2010 |
ASTELLAS PHARMA INC. COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF OSI PHARMACEUTICALS FOR $52 PER SHARE IN CASH
|
March 01, 2010 |
ASTELLAS PHARMA INC. OFFERS TO ACQUIRE OSI PHARMACEUTICALS FOR $52.00 PER SHARE IN CASH
|
January 15, 2010 |
FDA EXTENDS REVIEW PERIOD FOR TARCEVA APPLICATION FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
January 13, 2010 |
SUMAVELTM DOSEPROTM AVAILABLE IN THE UNITED STATES TO TREAT ACUTE MIGRAINE AND CLUSTER HEADACHES
|
January 12, 2010 |
OSI PHARMACEUTICALS, INC. ANNOUNCES FOURTH QUARTER AND 2009 FULL YEAR TARCEVA SALES AT JP MORGAN HEALTHCARE CONFERENCE
|
December 29, 2009 |
U.S. PATENT AND TRADEMARK OFFICE GRANTS REISSUED PATENT REPLACING OSI PHARMACEUTICALS' TARCEVA® COMPOSITION OF MATTER PATENT
|
December 16, 2009 |
FDA ADVISORY COMMITTEE RECOMMENDS AGAINST APPROVING TARCEVA FOR FIRST-LINE MAINTENANCE USE IN ADVANCED NON-SMALL CELL LUNG CANCER
|
December 07, 2009 |
ASTELLAS INDUCTED INTO NATIONAL MINORITY TRANSPLANT HALL OF FAME MOTTEP HONORS ASTELLAS FOR COMMITMENT TO TRANSPLANT COMMUNITY
|
November 16, 2009 |
OSI PHARMACEUTICALS ANNOUNCES TARCEVA TO BE REVIEWED BY THE FDA'S ONCOLOGIC DRUGS
ADVISORY COMMITTEE FOR USE AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER |
November 05, 2009 |
THERAVANCE AND ASTELLAS ANNOUNCE THE COMMERCIAL LAUNCH OF
VIBATIVTM (telavancin) IN THE UNITED STATES
|
October 28, 2009 |
CARDIOME AND ASTELLAS ANNOUNCE INITIATION OF PATIENT ENROLMENT IN ACT 5 TRIAL
|
October 26, 2009 |
DONATE LIFE ILLINOIS, ASTELLAS AND THE CHICAGO BEARS PARTNER TO
TACKLE THE SHORTAGE IN HONOR OF BEARS LEGEND, WALTER PAYTON
|
October 22, 2009 |
ZOGENIX AND ASTELLAS ANNOUNCE DATA PUBLISHED SHOWING THE
BENEFITS OF SUMAVELTM DOSEPROTM NEEDLE-FREE DELIVERY SYSTEM
|
October 02, 2009 |
NEW ANALYSIS SUPPORTS TOLERABILITY OF LEXISCAN® (regadenoson) INJECTION FOR PHARMACOLOGIC MYOCARDIAL PERFUSION IMAGING STUDIES
|
|
September 22, 2009
|
ASTELLAS AWARDS EDUCATIONAL SCHOLARSHIPS TO SIX TRANSPLANT RECIPIENTS WHO EMBODY THE SPIRIT OF GIVING BACK
|
|
September 21, 2009
|
ASTELLAS AND THE NATIONAL SCIENCE TEACHERS ASSOCIATION ANNOUNCE 2009 CLASS OF LOCAL SCIENCE EDUCATORS
|
|
September 17, 2009
|
U.S. PATENT AND TRADEMARK OFFICE ISSUES A NOTICE OF ALLOWANCE IN OSI PHARMACEUTICALS' REISSUE APPLICATION ON TARCEVA(R) COMPOSITION OF MATTER PATENT |
|
September 15, 2009
|
ASTELLAS CELEBRATES THE MIRACLE OF TRANSPLANTATION BY SENDING FIVE RECIPIENTS TO THE 2010 ROSE PARADE®
|
|
September 11, 2009
|
THERAVANCE AND ASTELLAS ANNOUNCE FDA APPROVAL OF VIBATIV™ (telavancin) FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
|
|
August 17, 2009
|
CHICAGO MAYOR HONORS ASTELLAS' EXCELLENCE IN LEARNING, DEVELOPMENT
|
|
August 13, 2009
|
UPDATE ON ASTELLAS' REQUEST FOR RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS
|
|
August 10, 2009
|
ASTELLAS SEEKS RIGOROUS TESTING AND SAFETY-RELATED LABELING FOR ANTI-REJECTION MEDICATIONS UNIQUE NEEDS OF TRANSPLANT PATIENTSREQUIRE SPECIAL CARE TO PRESERVE THEIR GIFT OF LIFE
ADDITIONAL CLINICAL TRIAL TO BE CONDUCTED FOR KYNAPID UNDER FDA SPECIAL PROTOCOL AGREEMENT
|
|
August 1, 2009
|
NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA EXTENDED SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY |
|
July 13, 2009
|
NEW DATA FROM PHASE III SATURN STUDY SHOWED TARCEVA IMPROVED OVERALL SURVIVAL WHEN USED IMMEDIATELY AFTER INITIAL CHEMOTHERAPY IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
|
July 6, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA |
|
August 3, 2009
|
ZOGENIX AND ASTELLAS ENTER EXCLUSIVE CO-PROMOTION AGREEMENT IN THE US
FOR NEWLY APPROVED SUMAVELTM DOSEPROTM
|
|
July 7, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF A TARCEVA(R) SUPPLEMENTAL NEW DRUG APPLICATION IN PANCREATIC CANCER FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION; TARCEVA'S SNDA IS GRANTED PRIORITY REVIEW DESIGNATION BY THE FDA |
|
June 25, 2009
|
ASTELLAS INFORMS CUSTOMERS OF MARKET WITHDRAWAL OF SPECIFIC PRODUCT LOTS
|
|
June 15, 2009
|
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA SUPPLEMENTAL NEW DRUG APPLICATION FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION |
|
June 04, 2009
|
ASTELLAS ADDS CNS THERAPY AREA LEADER TO GLOBAL R&D TEAM
|
|
June 01, 2009
|
ASTELLAS HIRES NEW VICE PRESIDENT OF COMPLIANCE
|
|
May 30, 2009
|
DATA FROM THE PHASE III ATLAS STUDY SHOW TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER |
|
May 28, 2009
|
ASTELLAS RECEIVES FDA APPROVAL FOR USE OF PROGRAF® (TACROLIMUS) IN CONJUNCTION WITH MYCOPHENOLATE MOFETIL (MMF) IN KIDNEY TRANSPLANT RECIPIENTS
|
|
May 28, 2009
|
ASTELLAS ANNOUNCES NEW VICE PRESIDENT OF MARKETING
|
|
May 28, 2009
|
PHASE 3 TRIAL INITIATED TO EVALUATE COMBINATION THERAPY OF NEXAVAR(R) AND TARCEVA(R) IN PATIENTS WITH LIVER CANCER |
|
May 14, 2009
|
DATA FROM THE PHASE III SATURN STUDY SHOW TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL WHEN USED AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER |
|
April 1, 2009
|
ASTELLAS APPOINTS NEW US PRESIDENT AND CEO
|
|
March 31, 2009
|
ASTELLAS LAUNCHES VAPRISOL® (CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA
|
|
March 19, 2009
|
OSI PHARMACEUTICALS SUBMITS SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA AS A FIRST-LINE MAINTENANCE THERAPY IN ADVANCED NON-SMALL CELL LUNG CANCER |
|
March 16, 2009
|
ASTELLAS TO TERMINATE OFFER FOR CV THERAPEUTICS
|
|
March 6, 2009
|
ASTELLAS TO NOMINATE TWO DIRECTORS AND SUBMIT PROPOSAL TO REMOVE REMAINING FOUR DIRECTORS OF CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS FILES LAWSUIT AGAINST CV THERAPEUTICS
|
|
February 27, 2009
|
ASTELLAS COMMENCES TENDER OFFER TO ACQUIRE ALL OUTSTANDING SHARES OF CV THERAPEUTICS FOR $16 PER SHARE IN CASH
|
|
February 23, 2009
|
ASTELLAS PHARMA ISSUES STATEMENT REGARDING CV THERAPEUTICS REJECTION OF ALL-CASH PROPOSAL
|
|
February 10, 2009
|
OSI PHARMACEUTICALS ANNOUNCES NOTIFICATION OF ANDA FILING FOR TARCEVA |
|
February 2, 2009
|
PHASE III STUDY SHOWED TARCEVA IN COMBINATION WITH AVASTIN AS FIRST-LINE MAINTENANCE THERAPY IMPROVED PROGRESSION-FREE SURVIVAL IN ADVANCED LUNG CANCER |
|
January 27, 2009
|
ASTELLAS PROPOSES TO ACQUIRE CV THERAPEUTICS FOR $16 PER SHARE IN CASH
|
|
November 26, 2008
|
TARCEVA® (ERLOTINIB) ENDORSED BY THE U.K.'S NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE FOR USE IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER |
|
November 7, 2008
|
PHASE III STUDY (SATURN) SHOWED TARCEVA IMPROVED PROGRESSION-FREE SURVIVAL AS A FIRST-LINE MAINTENANCE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER |
|
October 22, 2008
|
FDA APPROVES ASTELLAS' VAPRISOL® CONIVAPTAN HYDROCHLORIDE INJECTION) PREMIXED IN 5% DEXTROSE FOR THE TREATMENT OF HYPONATREMIA |
|
October 14, 2008
|
ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2009 ROSE PARADE®
|
|
October 06, 2008
|
GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE TOPLINE RESULTS FROM PHASE III STUDY EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA AS SECOND-LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER
|
|
October 01, 2008
|
ASTELLAS JOINS FORCES WITH THE NATIONAL SCIENCE TEACHERS ASSOCATION TO SUPPORT LOCAL SCIENCE EDUCATORS
|
|
August 11, 2008
|
CARDIOME AND ASTELLAS ANNOUNCE RECEIPT OF FDA APPROVABLE LETTER FOR KYNAPIDTM
|
|
June 24, 2008
|
ASTELLAS LAUNCHES LEXISCANTM (REGADENOSON) INJECTION FOR USE AS A PHARMACOLOGIC STRESS AGENT IN RADIONUCLIDE
MYOCARDIAL PERFUSION IMAGING (MPI)
|
|
April 10, 2008
|
CV THERAPEUTICS AND ASTELLAS ANNOUNCE FDA APPROVAL FOR LEXISCANTM (REGADENOSON) INJECTION
|
|
March 25, 2008
|
CIRCULATION PUBLISHES DATA SHOWING KYNAPID (VERNAKALANT HYDROCHLORIDE) INJECTION RAPIDLY CONVERTED SHORT-DURATION ATRIAL FIBRILLATION TO SINUS RHYTHM
|
|
Feburary 27, 2008
|
OSI PHARMACEUTICALS SEEKS TO STRENGTHEN TARCEVA PATENT BY FILING RE-ISSUE APPLICATION WITH THE U.S. PATENT AND TRADEMARK OFFICE
|
|
January 22, 2008
|
FDA APPROVES ADDITIONAL INDICATION FOR ASTELLAS MYCAMINE®
|
|
January 21, 2008
|
CARDIOME AND ASTELLAS ANNOUNCE REGULATORY UPDATE
|
|
December 14, 2007
|
OSI PHARMACEUTICALS ANNOUNCES LAUNCH DATE OF TARCEVA(R) (ERLOTINIB) IN JAPAN
|
|
December 11, 2007
|
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF KYNAPID FOR ACUTE ATRIAL FIBRILLATION
|
|
November 7, 2007
|
STUDY SHOWS VERNAKALANT HYDROCHLORIDE IS EFFECTIVE IN CONVERSION TO NORMAL HEART RHYTHM IN ATRIAL FIBRILLATION PATIENTS FOLLOWING CARDIAC SURGERY
|
|
October 25, 2007
|
STUDY SHOWS VAPRISOL® IS EFFECTIVE IN INCREASING SERUM SODIUM LEVELS AND WELL-TOLERATED IN PATIENTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIA
|
|
October 22, 2007
|
TARCEVA(R) (ERLOTINIB) EARNS APPROVAL FOR LUNG CANCER PATIENTS IN JAPAN
|
|
October 22, 2007
|
ADENOSCAN® PATENT LAWSUITS SETTLED
|
|
October 22, 2007
|
THERAVANCE RECEIVES FDA APPROVABLE LETTER FOR TELAVANCIN FOR THE TREATMENT OF COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
|
|
October 17, 2007
|
ASTELLAS PHARMA US, INC. AND THE INTERNATIONAL TRANSPLANT NURSES SOCIETY (ITNS) COLLABORATE ON CONTENT FOR
TRANSPLANT EXPERIENCE PROGRAM
|
|
October 15, 2007
|
OSI PHARMACEUTICALS PROVIDES ADDITIONAL INFORMATION ABOUT US SALES OF TARCEVA
|
|
October 11, 2007
|
ASTELLAS RIDE OF A LIFETIME CONTEST SENDS FIVE TRANSPLANT RECIPIENTS TO RIDE FLOAT IN 2008 ROSE PARADE
|
|
September 18, 2007
|
OSI PHARMACEUTICALS ANNOUNCES PATENT TERM EXTENSION FOR TARCEVA(R) (ERLOTINIB)
|
|
September 7, 2007
|
OSI PHARMACEUTICALS SUMMARIZES DATA PRESENTED ON TARCEVA(R) (ERLOTINIB) AT THE 12TH WORLD CONGRESS ON LUNG CANCER MEETING
|
|
June 5, 2007
|
OSI PHARMACEUTICALS SUMMARIZES DATA ON TARCEVA(R) (ERLOTINIB) AT THE 2007 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING
|
|
April 25, 2007
|
OSI PHARMACEUTICALS ANNOUNCES PIVOTAL PHASE III TARCEVA(R) STUDY PUBLISHED IN THE JOURNAL OF CLINICAL ONCOLOGY SHOWED SURVIVAL IMPROVEMENT IN PATIENTS WITH PANCREATIC CANCER
|
|
March 02, 2007
|
FDA APPROVES ASTELLAS VAPRISOL® FOR THE TREATMENT OF HYPERVOLEMIC HYPONATREMIA
|
|
February 26, 2007
|
Astellas Pharma US, Inc.'s "TRANSPLANT EXPERIENCE" PROGRAM RECEIVES NATIONAL RECOGNITION
|
|
February 19, 2007
|
CARDIOME AND ASTELLAS ANNOUNCE ACCEPTANCE OF NDA FOR REVIEW |
|
January 29, 2007
|
OSI PHARMACEUTICALS ANNOUNCES EUROPEAN REGULATORY APPROVAL OF TARCEVA(R) FOR TREATMENT OF PATIENTS WITH PANCREATIC CANCER |
|
November 15, 2006
|
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA(R) RECEIVED POSITIVE OPINION FROM HEALTH AUTHORITIES IN EUROPEAN UNION FOR THE TREATMENT OF PATIENTS WITH PANCREATIC CANCER |
|
September 21, 2006
|
OSI PHARMACEUTICALS LAUNCHES STUDY OF TARCEVA(R) AS ADJUVANT TREATMENT FOR NON-SMALL CELL LUNG CANCER |
|
October 29, 2006
|
ASTELLAS PHARMA US, INC., GLAXOSMITHKLINE, AND VESIcare® (SOLIFENACIN SUCCINATE) SPONSOR THE #18 RACE CAR AT ATLANTA MOTOR SPEEDWAY TO RAISE AWARENESS ABOUT OVERACTIVE BLADDER |
|
July 27, 2006
|
OSI PHARMACEUTICALS ANNOUNCES THAT ROCHE HAS RECEIVED NEGATIVE CHMP OPINION IN EUROPEAN UNION ON TARCEVA(R) IN PANCREATIC CANCER |
|
July 25, 2006
|
STUDY DEMONSTRATES IMPROVED RENAL FUNCTION AND LIPID VALUES IN KIDNEY TRANSPLANT PATIENTS ON PROGRAF ® COMPARED TO PATIENTS TAKING NEORAL ® |
|
June 6, 2006
|
OSI SUMMARIZES CLINICAL DATA ON TARCEVA(R) AT THE 2006 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) MEETING |
|
June 5, 2006
|
RESULTS FROM A RANDOMIZED PHASE II TRIAL SUGGESTED THE COMBINATIONS OF AVASTIN(R) PLUS TARCEVA(R) AND AVASTIN PLUS CHEMOTHERAPY IMPROVED PROGRESSION- FREE SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER |
|
April 26, 2006
|
ASTELLAS LAUNCHES VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA IN HOSPITALIZED PATIENTS |
|
April 17, 2006
|
OSI PHARMACEUTICALS ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TARCEVA(R) IN JAPAN |
|
April 3, 2006
|
ASTELLAS TO ACQUIRE AMEVIVE® (ALEFACEPT) |
|
April 1, 2006
|
ASTELLAS RECEIVES FDA APPROVAL OF PROGRAF® (TACROLIMUS) FOR USE IN HEART TRANSPLANT RECIPIENTS |
|
March 31, 2006
|
NEW DRUG APPLICATION SUBMITTED FOR RSD1235 |
|
Feburary 1, 2006
|
OSI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER NET SALES FOR TARCEVA(R)'S INTERNATIONAL LAUNCH; TARCEVA WORLD-WIDE SALES REACHED $309 MILLION IN 2005 |
|
January 19, 2006
|
ASTELLAS EDUCATES AND INFORMS PHYSICIANS AND PATIENTS ON CHANGES TO PROTOPIC LABEL IN U.S. |
|
January 11, 2006
|
OSI PHARMACEUTICALS ANNOUNCES NET U.S. TARCEVA(R) SALES FOR FOURTH QUARTER AND YEAR-END 2005; NARROWS MACUGEN(R) GUIDANCE & UPDATES CASH POSITION ON BALANCE SHEET |
|
December 30, 2005
|
FDA APPROVES ASTELLAS' VAPRISOL® FOR THE TREATMENT OF EUVOLEMIC HYPONATREMIA |
|
November 7, 2005
|
THERAVANCE AND ASTELLAS TO COLLABORATE ON TELAVANCIN, INVESTIGATIONAL ANTIBIOTIC FOR SERIOUS INFECTIONS |
|
November 3, 2005
|
MULTIMEDIA NEWS RELEASE -- FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE CHEMOTHERAPY FOR TREATMENT OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC CANCER |
|
November 2, 2005
|
FDA APPROVES TARCEVA(R) IN COMBINATION WITH GEMCITABINE CHEMOTHERAPY FOR TREATMENT OF LOCALLY ADVANCED, INOPERABLE OR METASTATIC PANCREATIC CANCER; TARCEVA NOW APPROVED FOR ADVANCED NON-SMALL CELL LUNG CANCER AND PANCREATIC CANCER |
|
October 19, 2005
|
CARDIOME AND ASTELLAS INITIATE ACT 4 STUDY |
|
October 12, 2005
|
OSI REITERATES CONFIDENCE IN TARCEVA |
|
September 21, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) GRANTED APPROVAL IN THE EUROPEAN UNION FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER |
|
September 13, 2005
|
FDA ADVISORY PANEL RECOMMENDS TARCEVA(R) APPROVAL FOR PANCREATIC CANCER; COMMITTEE SUPPORTS NEW INDICATION FOR EGFR INHIBITOR TARCEVA |
|
August 10, 2005
|
RAGADENOSON MEETS PRIMARY ENDPOINT IN FIRST PHASE 3 TRIAL |
|
August 8, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA(R) TO BE REVIEWED BY THE FDA'S ONCOLOGIC DRUGS ADVISORY COMMITTEE FOR USE IN PANCREATIC CANCER |
|
July 13, 2005
|
OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED APPROVAL IN CANADA FOR THE TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER
|
|
June 27, 2005
|
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA-R- RECEIVES POSITIVE OPINION IN EU FOR THE TREATMENT OF PATIENTS WITH ADVANCED LUNG CANCER
|
|
June 2, 2005
|
OSI PHARMACEUTICALS ANNOUNCES ISSUANCE OF ADDITIONAL U.S. PATENT FOR TARCEVA; EXTENDS PATENT EXCLUSIVITY
|
|
May 24, 2005
|
THREE CLINICAL STUDIES DEMONSTRATE ONCE-DAILY MODIFIED RELEASE PROGRAF® FORMULA TO BE PROMISING TREATMENT OPTION |
|
May 24, 2005
|
NEW STUDIES OF IMMUNOSUPPRESSIVE REGIMENS LIMITING OR AVOIDING THE USE OF STEROIDS SHOW EXCELLENT GRAFT SURVIVAL IN TRANSPLANT RECIPIENTS ON A PROGRAF®-BASED (TACROLIMUS) REGIMEN
|
|
May 17, 2005
|
DATA FROM TARCEVA CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
|
|
May 16, 2005
|
DATA FROM TARCEVA-TM- CLINICAL TRIAL PROGRAM PRESENTED AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING; EGFR AMPLIFICATION / MUTATION ANALYSIS FROM THE REGISTRATION BR.21 TRIAL PRESENTED
|
|
May 14, 2005
|
PHASE III STUDY OF TARCEVA IN COMBINATION WITH CHEMOTHERAPY IMPROVES SURVIVAL IN PANCREATIC CANCER PATIENTS
|
|
May 13, 2005
|
ANTI-FUNGAL AGENT MYCAMINETM AVAILABLE TO PHYSICIANS
|
|
May 2, 2005
|
OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE FILING OF A SUPPLEMENTAL NEW DRUG APPLICATION TO THE FDA FOR TARCEVA -TM- IN PANCREATIC CANCER
|
|
April 1, 2005
|
YAMANOUCHI, FUJISAWA UNITE TO FORM ASTELLAS PHARMA US, INC., NORTH AMERICAN HEADQUARTERS TO BE IN CHICAGO
|
March 22, 2005 |
OSI PHARMACEUTICALS ANNOUNCES TARCEVA GRANTED FIRST EUROPEAN APPROVAL IN SWITZERLAND; FIRST AND ONLY AGENT APPROVED IN ITS CLASS TO SHOW A SURVIVAL BENEFIT |
January 27, 2005 |
DATA FROM PHASE III STUDY SHOW TARCEVA PLUS GEMCITABINE SIGNIFICANTLY IMPROVES SURVIVAL COMPARED TO GEMCITABINE ALONE IN ADVANCED PANCREATIC CANCER PATIENTS |
November 22, 2004 |
OSI PHARMACEUTICALS ANNOUNCES LAUNCH OF TARCEVA-TM |
November 18, 2004 |
FDA APPROVES TARCEVA-TM- FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER; ONLY TARGETED EGFR THERAPY SHOWN TO IMPROVE SURVIVAL IN ADVANCED NON-SMALL CELL LUNG CANCER |
September 30, 2004 |
OSI PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF TARCEVA NEW DRUG APPLICATION FOR REVIEW BY THE U.S. FOOD AND DRUG ADMINISTRATION |
September 20, 2004 |
TARCEVA PLUS GEMCITABINE IMPROVES SURVIVAL COMPARED TO GEMCITABINE ALONE IN FIRST-LINE PANCREATIC CANCER PATIENTS |
September 10, 2004 |
GENENTECH AND OSI PHARMACEUTICALS INITIATE PHASE IIIB CLINICAL TRIAL OF TARCEVA IN ADVANCED NON-SMALL CELL LUNG CANCER |
August 26, 2004 |
OSI PHARMACEUTICALS ANNOUNCES ROCHE FILING OF TARCEVA -TM- MARKETING APPLICATION WITH EUROPEAN HEALTH AUTHORITIES |
August 2, 2004 |
OSI PHARMACEUTICALS AND GENENTECH ANNOUNCE COMPLETION OF NEW DRUG APPLICATION FOR FDA APPROVAL OF TARCEVA |
June 29, 2004 |
OSI PHARMACEUTICALS ANNOUNCES THAT TARCEVA HAS BEEN ACCEPTED INTO THE FDA'S PILOT 1 PROGRAM |
July 16, 2004 |
OSI PHARMACEUTICALS AND GENENTECH ENTER INTO CO-PROMOTION AND MANUFACTURING AGREEMENTS FOR TARCEVA |
June 5, 2004 |
EARLY CLINICAL DATA EVALUATING THE COMBINATION OF AVASTIN AND TARCEVA YIELD INITIAL PROMISING RESULTS IN SEVERAL CANCERS |
April 26, 2004 |
TARCEVA EXTENDS SURVIVAL OF PATIENTS WITH RELAPSED NON-SMALL CELL LUNG CANCER |
| March 19, 2004 |
OSI PHARMACEUTICALS INITIATES PHASE II STUDY OF TARCEVA IN NON-SMALL CELL LUNG CANCER PATIENTS WITH POOR PERFORMANCE STATUS |
January 21, 2004 |
OSI PHARMACEUTICALS INITIATES 'ROLLING' SUBMISSION OF A NEW DRUG APPLICATION WITH THE FDA FOR TARCEVA-TM- IN NON-SMALL CELL LUNG CANCER |
November 11, 2003 |
OSI PHARMACEUTICALS INITIATES PHASE II 'DOSE-TO-RASH' DOSE ESCALATION STUDY FOR TARCEVA--ERLOTINIB HCL-- |
October 1, 2003 |
PHASE III TRIALS OF TARCEVA PLUS CHEMOTHERAPY IN FIRST-LINE NON-SMALL CELL LUNG CANCER DO NOT MEET PRIMARY EFFICACY ENDPOINT |
August 8, 2003 |
TARCEVA -- ERLOTINIB HCL -- PHASE II CLINICAL TRIAL INITIATED IN PATIENTS WITH MALIGNANT GLIOMA |
June 3, 2003 |
OSI SUMMARIZES KEY CLINICAL DATA FOR TARCEVA - ERLOTINIB HCL - PRESENTED AT ASCO |
May 31, 2003 |
TARCEVA -- ERLOTINIB HCL -- SHOWS ENCOURAGING SAFETY PROFILE AND ACTIVITY IN PHASE I CLINICAL STUDY IN PATIENTS WITH MALIGNANT GLIOMA |
April 10, 2003 |
OSI PHARMACEUTICALS UPDATES INVESTORS ON STATUS OF TARCEVA DEVELOPMENT PROGRAM |
January 30, 2003 |
OSI PHARMACEUTICALS ANNOUNCES TARCEVA INTERNATIONAL PHASE III REFRACTORY / ADVANCED NON-SMALL CELL LUNG CANCER CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL |
January 28, 2003 |
OSI PHARMACEUTICALS ANNOUNCES TARCEVA; INTERNATIONAL PHASE III PANCREATIC CANCER CLINICAL TRIAL HAS REACHED ITS TARGET ENROLLMENT GOAL |
September 23, 2002 |
OSI PHARMACEUTICALS RECEIVES SECOND FDA FAST-TRACK DESIGNATION FOR TARCEVA; ANNOUNCES AMENDMENTS TO TARCEVA DEVELOPMENT PLAN |
September 12, 2002 |
INTERNATIONAL TRIAL EVALUATING TARCEVA IN LUNG CANCER COMPLETES PATIENT ENROLLMENT |
August 19, 2002 |
OSI PHARMACEUTICALS AND GENENTECH PROVIDE UPDATE ON STATUS OF TARCEVA ROGRAM |
August 1, 2002 |
TARCEVA U.S. PHASE III NON-SMALL CELL LUNG CANCER CLINICAL TRIAL COMPLETES PATIENT ENROLLMENT |
May 14, 2002 |
GENENTECH AND OSI PHARMACEUTICALS ANNOUNCE FDA FAST-TRACK DESIGNATION FOR TARCEVA |
May 2, 2002 |
OSI PHARMACEUTICALS ANNOUNCES COMPLETION OF INITIAL COHORT IN PHASE III PANCREATIC CANCER TRIAL FOR TARCEVA |
